Breaking news on muscular_dystrophy
MDA Activities Focus Attention On National ALS Awareness Month published
Fri, 02 May 2008 05:00:00 PDT
Throughout the month of May, the Muscular Dystrophy Association will highlight the 17th annual national ALS Awareness Month by hosting events in communities across the country and disseminating information about amyotrophic lateral sclerosis, or Lou Gehrig's disease. ALS is a deadly disease that attacks the nerve cells that control voluntary muscles, causing progressive weakness and eventually paralysis.
Drug Targets Identified In Limb-Girdle Muscular Dystrophy And Other Conditions published
Thu, 01 May 2008 02:00:00 PDT
A team of French and German researchers report in the May 2008 print issue of The FASEB Journal (http://www.fasebj.org/) that people with limb-girdle muscular dystrophy are missing a protein called c-FLIP, which the body uses to prevent the loss of muscle tissue.
Muscular Dystrophy Campaign At Naidex Exhibition, UK published
Tue, 29 Apr 2008 02:00:00 PDT
The Muscular Dystrophy Campaign will be exhibiting at NAIDEX 2008, the UK's largest event for homecare, disability and rehabilitation. We will be at stand C86 providing information for all visitors to the NEC in Birmingham from 29 April to 1 May.
PTC Therapeutics Announces Initiation Of Phase 2b Registration-Directed Clinical Trial Of PTC124 In Duchenne/Becker Muscular Dystrophy published
Thu, 24 Apr 2008 00:00:00 PDT
PTC Therapeutics, Inc. (PTC), today announced the initiation of an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.
Knopp Neurosciences Initiates Phase 2 Study Of KNS-760704 In Amyotrophic Lateral Sclerosis published
Thu, 10 Apr 2008 01:00:00 PDT
Knopp Neurosciences Inc. ("Knopp") said it initiated the first Phase 2 study of KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The study is designed as a two-part, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of KNS-760704 oral tablets. It will be conducted at approximately 20 centers in the U.S.
More Genes For Lou Gehrig's Disease Identified published
Tue, 08 Apr 2008 00:00:00 PDT
In recent months a spate of mutations have been found in a disease protein called TDP-43 that is implicated in two neurodegenerative disorders: amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, and certain types of frontotemporal dementia (FTD). These mutations could potentially become candidates for drug targets.
Discovery Of Role Of Rare Gene Mutations In Schizophrenia published
Mon, 31 Mar 2008 03:00:00 PDT
Using an important new method that can be applied in the study of other psychiatric illnesses, scientists at Cold Spring Harbor Laboratory (CSHL) in collaboration with colleagues at the University of Washington (UW) and the National Institute of Mental Health (NIMH), have identified multiple, individually rare gene mutations in people with schizophrenia that may help explain how that devastating illness is caused.
CytRx Submits Response To FDA Related To Clinical Program With Arimoclomol In ALS published
Thu, 27 Mar 2008 01:00:00 PDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that it has filed a response with the U.S. Food and Drug Administration (FDA) addressing issues cited by the FDA in its decision to place a clinical hold on the Company's Phase IIb clinical trial with arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
MDC Statement On Free Vote On The HFE Bill, UK published
Wed, 26 Mar 2008 01:00:00 PDT
Director of Campaigns and Policy at the Muscular Dystrophy Campaign, Robert Meadowcroft, said:"The Muscular Dystrophy Campaign regards the free vote as an issue for party management in Westminster. However, we do feel strongly that the Human Fertilisation and Embryology Bill is necessary to allow vital research to go forward."The Muscular Dystrophy Campaign is the only national charity focusing on all muscle diseases.
International Association Of Fire Fighters Directors' Award From MDA published
Mon, 24 Mar 2008 10:00:00 PDT
The Muscular Dystrophy Association awarded its highest philanthropic achievement honor, the MDA Directors' Award, to the International Association of Fire Fighters (IAFF). MDA President and CEO Gerald C. Weinberg presented the award to IAFF General President Harold Schaitberger at the Association's national headquarters in Tucson, Ariz.
ALS Aggregates Are Composed Of Only One Protein published
Sun, 23 Mar 2008 00:00:00 PDT
Researchers have provided a big new clue to help combat amyotrophic lateral sclerosis (ALS), deciphering that the dense protein aggregates that contribute to the nerve decay of ALS are composed of just one protein: superoxide dismutase (SOD1). While the aggregation of mutated SOD1, a protein that normally protects cells from free radical damage, is a tell-tale sign of familial ALS, the exact composition of these aggregates has been unclear.
Possible New Treatment Strategy For Muscular Dystrophy published
Tue, 18 Mar 2008 02:00:00 PDT
An investigational antiviral drug currently undergoing human trials in Europe for treating Hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy (MD). A research team led by Cincinnati Children's Hospital Medical Center reported their results using three different mouse models of MD in a letter posted online March 16 by the journal Nature Medicine.
Teva Provides Update On Glatiramer Acetate 40mg For Amyotrophic Lateral Sclerosis (ALS) published
Mon, 17 Mar 2008 01:00:00 PDT
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced final results from the global phase II GoALS trial. The study was designed to assess the safety, tolerability and efficacy of glatiramer acetate (GA) 40 mg, given once daily as a subcutaneous injection, in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis (ALS) patients.
MDC Launches Schools' Network, UK published
Wed, 12 Mar 2008 05:00:00 PDT
The Muscular Dystrophy Campaign has introduced a new Schools Network which is designed to help all children with neuromuscular conditions.We are asking for schools to register with us so that we can offer staff training sessions and appropriate support information. The network will help schools to provide support for all children with a neuromuscular condition.Part of the network is a schools forum, where ideas and information can be shared and exchanged.
Safety Assessment Of New Potential Treatment For Muscular Dystrophy published
Wed, 12 Mar 2008 02:00:00 PDT
Myostatin, a protein that blocks muscle growth, has shown promising results as a potential therapeutic target for treating muscular dystrophy in animal studies, where its inhibition led to increased muscle mass and strength. A new study, the first to evaluate a myostatin inhibitor in patients, assessed its safety in adults with muscular dystrophy and found that it was well-tolerated. The study was publishedbin Annals of Neurology (
Medical Careers Institute Raises Money For Muscular Dystrophy Association published
Wed, 12 Mar 2008 02:00:00 PDT
Medical Careers Institute, the School of Health Science at ECPI College of Technology, once again is participating in a Muscular Dystrophy Association Shamrock Sales Event. The event, which kicked off February 14th will run through March 17, 2008, includes a contest where Shamrocks are sold and then counted as "votes" towards a pie in the face for unlucky faculty.
Gene Therapy Study In Mice Shows Long-Term Muscle Improvements published
Tue, 11 Mar 2008 04:00:00 PDT
Injecting a gene responsible for making a specific protein into a mouse that's used as a model for muscular dystrophy can lead to long-term improvements in the animal's muscle size and strength, a new study shows.
Potential New Gene Therapy Strategy For Muscle-Wasting Diseases published
Tue, 11 Mar 2008 03:00:00 PDT
Investigators in The Research Institute at Nationwide Children's Hospital have identified the role of a protein that could potentially lead to new clinical treatments to combat musculoskeletal diseases, including Duchenne muscular dystrophy (DMD).Results of these studies appear in the March 11, 2008 issue of the Proceedings of the National Academy of Sciences.
Muscular Help Foundation Funds PHAB Places At Merchant Taylors, UK published
Fri, 07 Mar 2008 05:00:00 PDT
The Muscular Help Foundation (MHF) is delighted to be working for the first time with Merchant Taylors' School supporting their annual 2008 Easter Phab Week initiative that will see approximately twenty disabled young people (including some with muscular dystrophy) enjoy an inclusive residential programme of structured fun activities taking place at the school between 24 March and 29 March 2008.
Apprentice Star Supports Charity Week, UK published
Tue, 04 Mar 2008 14:00:00 PDT
Ansell Henry, star from series two of the Apprentice, showed his support for the Muscular Dystrophy Campaign by handing out prizes to the winning Morgan Hunt employees who raised the most money for people with muscle disease. The finale of the charity week partnership, held on Friday 29 February at the Octive8 bar in Covent Garden, was filled with a buzz as Morgan Hunt employees raised over £31,000 for the Muscular Dystrophy Campaign.
"Cross Border Patients Failed In Wales" Says Shadow Minister, UK published
Thu, 28 Feb 2008 04:00:00 PDT
David Jones, MP for Clwyd West and Shadow Minister for Wales, challenged Welsh Secretary, Paul Murphy, over difficulties experienced by Welsh patients suffering from muscle disease in obtaining treatment across in hospitals in England. In response, the Secretary of State accepted the "general thrust" of the criticism.
Gene Newly Linked To Inherited ALS May Also Play Role In Common Dementia published
Thu, 21 Feb 2008 00:00:00 PDT
Scientists at Washington University School of Medicine in St. Louis have linked a mutation in a gene known as TDP-43 to an inherited form of amyotrophic lateral sclerosis (ALS), the neurodegenerative condition often called Lou Gehrig's disease.Researchers found the connection intriguing because studies by other groups have revealed abnormalities in the TDP-43 protein in both sporadic and inherited ALS, as well as in several other neurodegenerative disorders.
Noted Neurologist To Chair MDA Medical Advisory Committee published
Wed, 20 Feb 2008 03:00:00 PDT
The Muscular Dystrophy Association announces that it has appointed neurologist Stanley H. Appel as chairman of its Medical Advisory Committee. A longtime MDA adviser and research grantee, Appel is director of the MDA/ALS Clinical Research Center at the Methodist Neurological Institute in Houston. He also is a professor in the Neurology Department at Baylor College of Medicine in Houston.
MDC Co-Hosts First Muscle Conference On Translational Research, UK published
Tue, 19 Feb 2008 04:00:00 PDT
Scientists, patients and clinicians from around the world recently attended the first Muscular Dystrophy Campaign conference on translational research.A two-day conference organised by the Muscular Dystrophy Campaign, in partnership with the new MRC Centre for Neuromuscular Diseases, took place on 1 and 2 February 2008 at the Institute of Child Health in London.
CytRx Receives FDA Correspondence Regarding Phase IIb Arimoclomol Clinical Trial In ALS published
Wed, 13 Feb 2008 02:00:00 PDT
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced receipt of a written correspondence from the U.S. Food and Drug Administration (FDA) providing clarification on the FDA's decision to place on clinical hold the Company's Phase IIb trial with arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
)
|
|
